UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.
In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. (NASDAQ: GEVA), and raised its price target from $42.00 to $50.00.
Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”
Synageva BioPharma Corp. closed on Tuesday at $42.85.
Latest Ratings for GEVA
|Mar 2015||JP Morgan||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.